Efficacy and Safety of Burosumab (KRN23) Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)

• Status: Completed
• Trial end date: 2019-07-15

Summary

The primary objective of this study is to evaluate the effect of KRN23 (burosumab) therapy in improving rickets in children with XLH compared with active control (oral phosphate/active vitamin D).

• Phase: Phase 3

Details

• Lead Sponsor: Ultragenyx Pharmaceutical Inc
• Collaborators: Kyowa Hakko Kirin Company, Limited; Kyowa Kirin Co., Ltd.
• Treatments: Ergocalciferols; Vitamin D; Vitamins